The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine

Jones, Franca R.; Hall, Eric R.; Tribble, David R.; Savarino, Stephen J.; Cassels, Frederick J.; Porter, Chad K.; Meza, Rina; Núñez, Gladys; Espinoza, Nereyda; Salazar, Milagros; Luckett, Rickey; Scott, Daniel A.

doi:10.1016/j.vaccine.2005.07.029

Cited by 17 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The limited adjuvant effect of the LT(R192G) in the present study was not caused by an inactivity of LT(R192G) as high mLTspecific titers were found in the LT(R192G) immunized groups and not in the non-immunized group. This adjuvant is reported as a powerful adjuvant for mucosal immunizations in mice (Gerber et al, 2001;Choi et al, 2002) and other animals (Burr et al, 2005;Jones et al, 2006). In pigs, LT(R192G) is shown to be an effective adjuvant for nasal immunization (Yuan et al, 2000(Yuan et al, , 2001), but has not yet been used in oral immunization.…”

Section: Discussionmentioning

confidence: 99%

Mucosal immunization of piglets with purified F18 fimbriae does not protect against F18+ Escherichia coli infection

Verdonck

Tiels

Gog

et al. 2007

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Post-weaning diarrhoea and oedema disease in weaned piglets are caused by infection with F4 + or F18 + Escherichia coli strains. There is no commercial vaccine available, but it is shown that oral immunization of weaned piglets with purified F4 fimbriae induces a protective mucosal immune response. In the present study, piglets were orally and nasally immunized with purified F18 fimbriae in the presence of the mucosal adjuvant LT(R192G) or CTA1-DD, respectively. This immunization could not lead to protection against F18 + E. coli infection. The induced F18-specific immune response was directed towards the major subunit FedA and weakly towards the adhesive subunit FedF. The results of these experiments demonstrate that it is difficult to induce protective immunity against F18+ E. coli using the whole fimbriae due to the low response against the adhesin. #

show abstract

Section: Discussionmentioning

confidence: 99%

Mucosal immunization of piglets with purified F18 fimbriae does not protect against F18+ Escherichia coli infection

Verdonck

Tiels

Gog

et al. 2007

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

show abstract

“…Stool samples were aliquoted and frozen at Ϫ70°C at the U.S. Air Force hospital at Incirlik Air Base. All specimens were shipped to the Naval Medical Research Unit 3 laboratory for processing and secretory-IgA determination (16,17). An immune response was defined as a Ն4-fold rise over the baseline titer.…”

mentioning

confidence: 99%

Case Series Study of Traveler's Diarrhea in U.S. Military Personnel at Incirlik Air Base, Turkey

Porter

Mohammady

Baqar

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

Military personnel with traveler's diarrhea (n = 202) while deployed to Incirlik Air Base, Turkey, from June to September 2002 were evaluated for pathogen-specific immune responses. Serologic and fecal immunoglobulin A (IgA) titers to enterotoxigenic Escherichia coli antigens (CS6, CS3, and LT) were quite low. In contrast, subjects with Campylobacter infections had high serologic and fecal IgA responses.

show abstract

“…The A. nancymaae model has been used to evaluate the immunogenicity and efficacy of several ETEC (15) and Campylobacter (14,27) vaccines. The attack rates in naive Aotus monkeys orally inoculated with 5 ϫ 10 11 to 7 ϫ 10 11 CFU of C. jejuni are typically Ն70%.…”

Section: Discussionmentioning

confidence: 99%

“…Both Aotus challenge models result in reproducible attack rates of Ն70% and are characterized by colonization of the gastrointestinal tract and the induction of diarrhea (14,15). The addition of a Shigella-Aotus challenge model would enable the testing of potential combination vaccines against the three most common enteric bacterial pathogens responsible for traveler's diarrhea.…”

mentioning

confidence: 99%

Development of an Aotus nancymaae Model for Shigella Vaccine Immunogenicity and Efficacy Studies

Gregory¹,

Kaminski²,

Lugo‐Roman³

et al. 2014

Infect Immun

View full text Add to dashboard Cite

Several animal models exist to evaluate the immunogenicity and protective efficacy of candidate Shigella vaccines. The two most widely used nonprimate models for vaccine development include a murine pulmonary challenge model and a guinea pig keratoconjunctivitis model. Nonhuman primate models exhibit clinical features and gross and microscopic colonic lesions that mimic those induced in human shigellosis. Challenge models for enterotoxigenic Escherichia coli (ETEC) and Campylobacter spp. have been successfully developed with Aotus nancymaae, and the addition of a Shigella-Aotus challenge model would facilitate the testing of combination vaccines. A series of experiments were designed to identify the dose of Shigella flexneri 2a strain 2457T that induces an attack rate of 75% in the Aotus monkey. After primary challenge, the dose required to induce an attack rate of 75% was calculated to be 1 ؋ 10 11 CFU. Shigella-specific immune responses were low after primary challenge and subsequently boosted upon rechallenge. However, preexisting immunity derived from the primary challenge was insufficient to protect against the homologous Shigella serotype. A successive study in A. nancymaae evaluated the ability of multiple oral immunizations with live-attenuated Shigella vaccine strain SC602 to protect against challenge. After three oral immunizations, animals were challenged with S. flexneri 2a 2457T. A 70% attack rate was demonstrated in control animals, whereas animals immunized with vaccine strain SC602 were protected from challenge (efficacy of 80%; P ‫؍‬ 0.05). The overall study results indicate that the Shigella-Aotus nancymaae challenge model may be a valuable tool for evaluating vaccine efficacy and investigating immune correlates of protection.

show abstract

The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine

Cited by 17 publications

References 19 publications

Mucosal immunization of piglets with purified F18 fimbriae does not protect against F18+ Escherichia coli infection

Mucosal immunization of piglets with purified F18 fimbriae does not protect against F18+ Escherichia coli infection

Case Series Study of Traveler's Diarrhea in U.S. Military Personnel at Incirlik Air Base, Turkey

Development of an Aotus nancymaae Model for Shigella Vaccine Immunogenicity and Efficacy Studies

Contact Info

Product

Resources

About